Drug intelligence / Profile preview

brivaracetam

Development stage: Approved
Lead developer: UCB
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Brivaracetam is a third-generation antiepileptic drug primarily used to treat partial onset seizures in adults, children, and infants 1 month of age and older. It is classified as a pyrrolidine anticonvulsant. Brivaracetam acts as a high-affinity ligand for synaptic vesicle protein 2A (SV2A), selectively binding to this target in the brain to decrease abnormal electrical activity and help control seizures. It may also have some inhibitory effect on voltage-dependent sodium channels. Brivaracetam is available as an oral tablet, oral solution, and intravenous injection[1][3][5]. The drug was developed by UCB and marketed under the brand name Briviact[5][9].

Brand names: Briviact
Other names: 布立西坦

Targets

SV2A (Synaptic vesicle glycoprotein 2A)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on brivaracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on brivaracetam.

Explore the full profile